Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of intangible assets like intellectual property (IP) will be fundamental to future biopharmaceutical financial success. The global nature and internal structure of biopharmaceutical multinational corporations (MNCs) means ...

The Great Recession in the U.S. not only marked a period of the longest and by many measures the largest economic downturn since The Great Depression of the 1930’s, but also altered assumptions by business executives about the relationship between recessions and biopharma industry drug demand. This white paper explores three questions about the future relationship of economic recessions to ...

The growing shift to specialty medicines in the US pharma market is well documented. Pricing issues are becoming more common and controversial, with questions being raised about the sustainability of increasing sales revenue mainly through pricing. Further, given the cost of newer specialty medicines, performance-based pharmaceutical pricing contracts through payers will become the norm. The ...

The pharmacy channel has been an under-studied area by drug companies relative to greater focus on physicians, managed care, hospitals, and patients/consumers. This paper sheds empirical light on the effects of potential pharmacist involvement and motivations in brand-to-generic drug substitutions driven by state pharmacy drug product selection (DPS) laws that have to be later reversed as seen in ...

Changes in emerging environmental trends facing the pharma industry are requiring companies to rethink different strategic and operational sales force plans that ultimately drive new outcome measures. Among these sales force changes are considerations to implement incentive compensation designs that move away from traditional Rx-volume measurement. Despite noted challenges, this paper explores ...

The stakeholders and factors that drive the ultimate prescribing of a medication have shifted considerably since the turn of the century. Technological advances (i.e., EMR), cost pressures, quality initiatives, government regulations, and other factors have contributed to the rise and expansion of Integrated Delivery Networks (IDNs). The independence that physicians once experienced in their own ...

Payers vary in their ability to assert formulary compliance. We will explore how tools and analytics can enable a pharmaceutical manufacturer to assess factors impacting formulary control and incorporate those findings when evaluating contracting opportunities. We apply these approaches to understand the various levers payers use to control product utilization and measure the direct and indirect ...